In April 2022, the Biden administration ordered 20 million doses of Pfizer’s antiviral Covid-19 treatment called Paxlovid. Now a study published in the New England Journal of Medicine shows it has “no measurable benefit” for the treatment of COVID-19 in patients 40 to 65-years of age.
Study: No Measurable Benefits from Paxlovid for People Aged 40 – 65
Written by The Conservative Treehouse